ichroma™ CA19-9

One of the most well known and the widely used biomarker in PDACs*

ichroma™ CA19-9 test benefits

Boditech Med provides diverse tumor marker panel to improve the diagnostic sensitivity and specificity

- Quantitative fluorescence immunoassay
- Fast test result in 12 min with small sample volume
- Easier to handle and storage stable

* **Pancreatic ductal adenocarcinoma (PDAC)**
The most prevalent neoplastic disease of the pancreas accounting for more than 90% of all pancreatic malignancies. Pancreatic cancer is crucial to diagnose or detect the recurrence of pancreatic cancer at its early stage since it's a very malignant disease.

BIO TECHNOLOGY boditech

What is CA19-9 test?

- Carbohydrate antigen 19-9, also known as Sialyl Lewis antigen A (sLeA), is a type of tumor marker and is protein found in the blood.
- Normal results are less than 37 U/mL and a high amount of CA19-9 is most often caused by pancreatic cancer.
- Can be elevated by other types of cancer such as colorectum, lung, liver and ovary.
- The most sensitive (79-81%) and specific (82-90%) tumor marker for pancreatic cancer compared to other tumor markers

Clinical Usefulness

- Currently there is no other excellent marker than CA19-9 in terms of sensitivity and specificity in pancreatic cancer
- The only clinically used marker for the management of PDAC (FDA-approved as a disease monitoring marker).
- Performs best to help diagnose or develop a prognosis, monitor the cancer response to treatment and to detect a reoccurrence in pancreatic cancer.

ichroma™ CA19-9 Specification

ichroma™ CA19-9 is a fluorescence immunoassay (FIA) for the quantitative determination of CA19-9.

Test principle	Fluorescence Immunoassay (FIA)
Sample type	Serum, plasma
Sample volume	10 µL
Assay time	12 min
Cut off	37 U/mL
Working range	8-1,000 U/mL
Storage and shelf life	Up to 20 months at 2-30 °C
Available platform	ichroma™ II, ichroma™ III, ichroma™ M2

Performance

ichroma™ CA19-9 showed reliable test result compared with laboratory equipment.



Ordering information

Product	Cat. No.
ichroma™ CA19-9	CFPC-139
ichroma™ CA19-9 Control	CFPC-358
ichroma™ II	FPRR021
ichroma™ III	FPRR037
ichroma™ M2	FPRR031

References

1) Chan, Alison, et al. "Validation of biomarkers that complement CA19. 9 in detecting early pancreatic cancer." Clinical Cancer Research 20.22 (2014): 5787-5795.
2) Orth, Michael, et al. "Pancreatic ductal adenocarcinoma: Biological hallmarks, current status, and future perspectives of combined modality treatment approaches." Radiation Oncology 14.1 (2019): 1-20.

EN_Rev00_CA19-9_ichroma_20221026_2P

BIO TECHNOLOGY boditech

43, Geodudanji 1-gil, Dongnae-myeon, Chuncheon-si, Gangwon-do, 24398, Korea
Tel: +82-33-243-1400 / Fax: +82-33-243-9373 / marketing@boditech.co.kr / www.boditech.co.kr